Evidence map›Paper›PMID 39267776›Full record

ReviewTheranostics2024

Theoretical basis, state and challenges of living cell-based drug delivery systems.

Wei Liu, Guowang Cheng, Hao Cui, Zhen Tian, Bowen Li, Yanhua Han, Jia-Xin Wu, Jie Sun, Yuyue Zhao, Tongkai Chen and 1 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Theranostics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Article
  8. Review
  9. Review
  10. Review
  11. Review
  12. Article
  13. Review
  14. Article
  15. [Advancement in neutrophil-based drug delivery systems].Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences · 2025
    Review
  16. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Wei LiuStomatological Hospital, School of Stomatology, Southern Medical University, Guangzhou, 510280, China.
Guowang ChengScience and Technology Innovation Center, Guangzhou University of Chinese Medicine, Guangzhou 510405, China.
Hao CuiStomatological Hospital, School of Stomatology, Southern Medical University, Guangzhou, 510280, China.
Zhen TianStomatological Hospital, School of Stomatology, Southern Medical University, Guangzhou, 510280, China.
Bowen LiStomatological Hospital, School of Stomatology, Southern Medical University, Guangzhou, 510280, China.
Yanhua HanScience and Technology Innovation Center, Guangzhou University of Chinese Medicine, Guangzhou 510405, China.
Jia-Xin WuScience and Technology Innovation Center, Guangzhou University of Chinese Medicine, Guangzhou 510405, China.
Jie SunStomatological Hospital, School of Stomatology, Southern Medical University, Guangzhou, 510280, China.
Yuyue ZhaoStomatological Hospital, School of Stomatology, Southern Medical University, Guangzhou, 510280, China.
Tongkai ChenScience and Technology Innovation Center, Guangzhou University of Chinese Medicine, Guangzhou 510405, China.
Guangtao YuStomatological Hospital, School of Stomatology, Southern Medical University, Guangzhou, 510280, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The therapeutic efficacy of drugs is determined, to a certain extent, by the efficiency of drug delivery. The low efficiency of drug delivery systems (DDSs) is frequently associated with serious toxic side effects and can even prove fatal in certain cases. With the rapid development of technology, drug delivery has evolved from using traditional frameworks to using nano DDSs (NDDSs), endogenous biomaterials DDSs (EBDDSs), and living cell DDSs (LCDDSs). LCDDSs are receiving widespread attention from researchers at present owing to the unique advantages of living cells in targeted drug delivery, including their excellent biocompatibility properties, low immunogenicity, unique biological properties and functions, and role in the treatment of diseases. However, the theoretical basis and techniques involved in the application of LCDDSs have not been extensively summarized to date. Therefore, this review comprehensively summarizes the properties and applications of living cells, elaborates the various drug loading approaches and controlled drug release, and discusses the results of clinical trials. The review also discusses the current shortcomings and prospects for the future development of LCDDSs, which will serve as highly valuable insights for the development and clinical transformation of LCDDSs in the future.

Indexed as

Drug Delivery SystemsAnimalsBiocompatible MaterialsDrug CarriersHumansNanoparticlesBiocompatible MaterialsDrug CarriersClinical transformationControlled drug releaseDrug loading approachesLiving cellsTargeted drug delivery

Identifiers

PMID39267776
PMCPMC11388066

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.